Skip to main content
. 2012 Mar 15;125(6):1556–1567. doi: 10.1242/jcs.095729

Fig. 4.

Fig. 4.

NR2AR activation mediates PTEN downregulation and TDP-43 upregulation in early stages after THA treatment. (A) Sample immunoblots (left) and summarized data (right) show that the NR2AR antagonist NVP-AAM077 (0.4 μM) but not the NR2BR antagonist Ro25-6981 (0.5 μM) reduces THA-induced PTEN downregulation at 3 days after 100 μM THA treatment (n=7 for each group; *P<0.05 vs control; **P>0.05 vs 3d/THA; #P<0.05 vs. 3d/THA; data are normalized to control). (B) Representative immunoblots (left) and summarized data (right) show that NVP-AAM077 (0.4 μM) but not Ro25-6981 (0.5 μM) prevented upregulation of TDP-43 expression at 3 days after 100 μM THA treatment (n=6 for each group; *P<0.05 vs control; #P<0.05 vs 3d/THA; data are normalized to control). (C) Sample immunoblots (left) and summarized data (right) show that bpV(pic) (100 nM) prevented NR2AR-inhibition-induced blockade of TDP-43 upregulation in cortical neurons at 3 days after 100 μM THA treatment (n=6 for each group; *P<0.05 vs control; **P<0.05 vs 3d/THA; #P<0.05 vs NVP-AAM077+3d/THA; data are normalized to control). All bar graphs show means ± s.e.m.